Zonisamide (ZNS) is frequently added on conventional epileptic therapy for refractory seizures.1) It is clinically important to clarify the influences of antiepileptic drugs on the serum ZNS concentration in a steady-state (C t ).Before investigating the influences on C t , it is preferable to clarify the relation between daily dose (D) and C t in the administration of ZNS alone. C t and D are expressed as a function of clearance. Body weight (W) or body surface area, corresponding to clearance, has been used as a substitute for clearance (transforming factor). D is transformed to a variable (transformed daily dose: DЈ) being divided by a transforming factor, C t is thus related to DЈ.The influences of antiepileptic drugs on C t /DЈ (level/dose (L/D) ratio) have been examined, but no regard has been paid to the influences of confounding factors such as age and sex. Employing W as a transforming factor, the L/D ratio (C t /(D/W) : C t /D W Ј ) was found to be dependent on age.2) The analyses based on C t /D W Ј were misleading because the patients might be grouped by age.3) If DЈ, which was related to C t without being affected by confounding factors, could be determined, it would be worth evaluating for clinical use.The authors showed that ideal body weight or extracellular water volume (V ECW ) could be used as a transforming factor to relate the serum concentration with the daily dose without an effect by confounding factors for valproic acid (VPA) 4) or carbamazepine (CBZ), 5) respectively. The influences of concomitant drug use on the serum concentration were evaluated quantitatively in all the patients without them being grouped by other confounding factors. 6,7) In this paper, V ECW also affected the L/D ratio of ZNS independent of confounding factors. Then the authors detected the drug affecting the L/D ratio and investigated its influence quantitatively.
METHODSWe collected data from epileptic patients, who were chronically treated with multiple oral administrations of ZNS (Excegran ® granules/tablets, Dainippon Pharmaceutical Co., Osaka, Japan) at Kagawa Medical University Hospital between April 1995 and May 1998 and at Kurashiki Central Hospital between April and September 1996. The total number of patients administered ZNS was 175. Patients with abnormal findings on hepatic and renal function tests were excluded. Blood samples were drawn 2 to 3 h after the last dosing in outpatients and 2 to 15 h in inpatients. The fluctuations of C t at different sampling times were considered to be negligible because of its long elimination half-life.
8)When there were multiple measurements for C t in one patient with the same prescribed drugs during the study period, the average value was used. The age, body weight, height and daily ZNS dose were treated in the same manner. When several varieties of drugs were prescribed in one patient, the count was taken as the number of patients. In both hospitals, C t was measured in duplicate by HPLC and the average value employed.Data analysis was performed by utilizing a sta...